A Phase I Study of Dasatinib With Bortezomib (Velcade) and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma.

Trial Profile

A Phase I Study of Dasatinib With Bortezomib (Velcade) and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Bortezomib; Dasatinib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jul 2012 Actual patient number changed from 14 to 16 as reported by ClinicalTrials.gov record.
    • 06 Jul 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 14 Jun 2010 Planned end date changed from 1 Jun 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top